Aedes-borne DiseasesNCT04343521
Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases
A study testing Targeted Indoor Residual Spraying (TIRS) in people with Aedes-borne Diseases and Dengue, run by Emory University at 1 site in Mexico.
Trial summary
The objective of this trial is evaluate the efficacy of Targeted Indoor Residual Spraying (TIRS) in preventing symptomatic disease caused by Aedes-borne diseases (ABDs) in children 2 to 15 years of age in the city of Merida, Yucatan State, Mexico. Read more about this study
- Who is it for?
- Ages 2 to 15 years
- Conditions the study is for
- Aedes-borne Diseases, Dengue, Chikungunya
- What is being tested?
- Targeted Indoor Residual Spraying (TIRS)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4,461 participants
- Where
- 1 siteMexico
- Study dates
- 3 Nov 2020to 28 Apr 2024
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 to 15 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Household Level Inclusion Criteria:
- Household is located within the bounds of a study cluster (5x5 city-block clusters)
- City block has at least 60% premises that are residential
- Individual Level Inclusion Criteria:
- 2 or more and up to 15 years of age at the time of initial enrollment
- Living in a house that consented to TIRS (for children in TIRS cluster)
Who cannot join
- Household Level Exclusion Criteria:
- Households where study personnel identify a security risk (i.e., site where drugs are sold, residents are always drunk or hostile)
- Sites where no residents spend time during the day (i.e. work 7days a week outside the home)
- Inability for a resident to provide informed consent
- Non-residential places (e.g., businesses, schools, markets, etc.)
- Individual Level Exclusion Criteria:
Show all 11Show fewer
- Less than 2 years of age or more than 15 years of age at the time of enrollment
- Not living in a house that consented to TIRS (for children in TIRS cluster)
- Having a medical condition that prevents implementation of study procedures
- Temporary visitor to household
- Plans to leave study area within next 12 months
Trial locations and contacts
1 site in 1 country.
About this study
The objective of this trial is evaluate the efficacy of Targeted Indoor Residual Spraying (TIRS) in preventing symptomatic disease caused by Aedes-borne diseases (ABDs) in children 2 to 15 years of age in the city of Merida, Yucatan State, Mexico.
Read the detailed description
Contemporaneous urban vector control (truck-mounted ultra-low volume spraying, thermal fogging, larviciding) has failed to contain dengue epidemics and to prevent the global range expansion of Aedes-borne diseases (ABDs: dengue, chikungunya, zika). Part of the challenge in sustaining effective ABD control emerges from the remarkable paucity of evidence about the epidemiological impact of any vector control method. Furthermore, the classic deployment of interventions in response to clinical cases fails to account for the important contribution of out-of-home human mobility and asymptomatic infections.
The trial will be conducted in the city of Merida extending ongoing longitudinal cohort to follow a population of 4,600 children 2-15 years old randomly allocated to receive either TIRS treatment or not. If efficacious, TIRS will drive a paradigm shift in Aedes control by: considering Ae. aegypti behavior to rationally guide insecticide applications; the change to preventive control (pre- ABD transmission season rather than in response to symptomatic cases); the use of third generation insecticides to which Ae. Aegypti is susceptible.
- Conditions
- Aedes-borne Diseases, Dengue, Chikungunya, Zika
- Being tested
- Targeted Indoor Residual Spraying (TIRS)
- Keywords
- Targeted Indoor Residual Spraying, Children, Dengue virus (DENV), Chikungunya virus (CHIKV), Zika virus (ZIKV), Ae. aegypti mosquito
- Medical subject headings
- Mosquito-Borne Diseases, Dengue, Chikungunya Fever, Zika Virus Infection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Targeted Indoor Residual Spraying (TIRS)Other
Also called Actellic 300CS
Spraying of insecticide Actellic 300CS will start in May or June extending for 1 to 2 months. Residents will be asked to temporarily leave the house during treatment and wait half an hour to one hour for the product to dry before re-entering the house. Insecticide application will follow strict protocol developed by the Centers for Disease Control and Prevention (CDC), Emory University, and the Universidad Autónoma de Yucatán.
| Study group | Role | What they receive |
|---|---|---|
| Targeted Indoor Residual Spraying (TIRS) | Experimental | All households in Targeted Indoor Residual Spraying (TIRS) clusters will be offered the intervention, and children in households that consent to TIRS will be recruited into this study arm. Receives: Other: Targeted Indoor Residual Spraying (TIRS) |
| Routine Aedes-borne Virus (ABV) Prevention and Control | No intervention | Households in the control clusters receive routine Aedes-borne virus (ABV) prevention and control, without Targeted Indoor Residual Spraying (TIRS). Children in the control households will be recruited into this study arm. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically
The number of symptomatic children with laboratory confirmed, by reverse transcription-polymerase chain reaction (RT-PCR) or immunoglobulin M/ immunoglobulin G (IgM/IgG) enzyme-linked immunosorbent assay (ELISA), Aedes-borne Viruses infections. The number of any Aedes-borne virus infection during three seasons of high transmission is described, as well as the number of Dengue virus (DENV), Chikungunya virus (CHIKV), Zika virus (ZIKV) and coinfections.
Measured: 18 months of active surveillance during high transmission seasons (each 6 months in duration) during 3 years (July through December in 2021, 2022, and 2023)
Secondary outcomes (7)
Number Positive Tests of Laboratory Confirmed Aedes-borne Viruses Infections By Season
Number of laboratory confirmed (IgG ELISA and neutralization testing) Aedes-borne Viruses (DENV, CHIKV and ZIKV) in annual surveillance samples.
Measured: Up to 36 months, during serosurvey seasons 2021-2022, 2022-2023, and 2023-2024
Ae. Aegypti Mosquito Infection Rate With Aedes-borne Viruses (DENV, CHIKV and ZIKV)
Ae. aegypti mosquito infection rate with Aedes-borne Viruses (DENV, CHIKV and ZIKV) assessed by the number of positive RT-PCR tests. Infection is mosquitoes is analyzed by collecting binary data (a mosquito pool is either infected or not) and transforming that into minimum infection rates (MIR) with the calculation: (1/number of mosquitoes in the pool) times 1000. Households were randomly selected for testing; houses were eligible for testing if they were located within the central blocks and had at least one child enrolled in the study.
Measured: Up to 6 months (mosquito pools were collected during the 6 months post TIRS spraying samplings in 2021)
Ae. Aegypti Indoor Entomological Index of Adult Mosquito Abundance
The Ae. aegypti indoor entomological index of adult mosquito presence/abundance is calculated as the number of adult mosquitoes per house. Higher values mean that more mosquitoes are found within houses.
Measured: Up to 36 months starting at the first TIRS application
Ae. Aegypti Indoor Entomological Index of Female Mosquito Abundance
The Ae. aegypti indoor entomological index of female mosquito presence/abundance is calculated as the number of female mosquitoes per house. Higher values mean that more mosquitoes are found within houses.
Measured: Up to 36 months starting at first TIRS application
Ae. Aegypti Indoor Entomological Index of Bloodfed Female Mosquito Abundance
The Ae. aegypti indoor entomological index of bloodfed female mosquito presence/abundance is calculated as the number of bloodfed female mosquitoes per house. Higher values mean that more mosquitoes are found within houses.
Measured: Up to 36 months starting at first TIRS application
Number of Households Where the Head of Household Would Recommend the Intervention
Acceptability of the intervention is determined through household surveys, for households that received the intervention. Acceptability is assessed as the number of households where the head of that household would recommend the intervention to others.
Measured: Post-intervention (up to 41 months and 26 days after the start of the intervention)
Number of Households With a Resident That Had a Reaction to the Insecticide
Safety of the intervention is assessed as the number of households receiving the TIRS intervention that had evidence of a household resident having a reaction possibly related to the insecticide, which was assessed and confirmed by study doctors.
Measured: Post-intervention (up to 41 months and 26 days after the start of the intervention)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2020
- Study start3 Nov 2020
- Primary completion28 Apr 2024
- Study completion28 Apr 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Aedes-borne DiseasesStudies of the same condition, open and under way.
- More trials run by Emory UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 4,461 participants (actual)
Sponsor and investigators
- Lead sponsor
- Emory University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Gonzalo Vazquez-Prokopec, Emory University
- Investigators
- Gonzalo Vazquez Prokopec, MD, Principal investigator, Emory University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04343521
- Sponsor's protocol ID
- IRB00108666
- Other IDs
- 1U01AI148069-01
- Status last verified
- Aug 2025
- First submitted
- 9 Apr 2020
- Last updated
- 18 Sep 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Deidentified individual participant data that underlie the results reported in publications of this study will be available for sharing with other researchers.
Publications
Manrique-Saide P, Dean NE, Halloran ME, Longini IM, Collins MH, Waller LA, Gomez-Dantes H, Lenhart A, Hladish TJ, Che-Mendoza A, Kirstein OD, Romer Y, Correa-Morales F, Palacio-Vargas J, Mendez-Vales R, Perez PG, Pavia-Ruz N, Ayora-Talavera G, Vazquez-Prokopec GM. The TIRS trial: protocol for a cluster randomized controlled trial assessing the efficacy of preventive targeted indoor residual spraying to reduce Aedes-borne viral illnesses in Merida, Mexico. Trials. 2020 Oct 8;21(1):839. doi: 10.1186/s13063-020-04780-7.
PubMed 33032661Che-Mendoza A, Gonzalez-Olvera G, Medina-Barreiro A, Arisqueta-Chable C, Bibiano-Marin W, Correa-Morales F, Kirstein OD, Manrique-Saide P, Vazquez-Prokopec GM. Efficacy of targeted indoor residual spraying with the pyrrole insecticide chlorfenapyr against pyrethroid-resistant Aedes aegypti. PLoS Negl Trop Dis. 2021 Oct 4;15(10):e0009822. doi: 10.1371/journal.pntd.0009822. eCollection 2021 Oct.
PubMed 34606519Dzul-Manzanilla F, Correa-Morales F, Che-Mendoza A, Palacio-Vargas J, Sanchez-Tejeda G, Gonzalez-Roldan JF, Lopez-Gatell H, Flores-Suarez AE, Gomez-Dantes H, Coelho GE, da Silva Bezerra HS, Pavia-Ruz N, Lenhart A, Manrique-Saide P, Vazquez-Prokopec GM. Identifying urban hotspots of dengue, chikungunya, and Zika transmission in Mexico to support risk stratification efforts: a spatial analysis. Lancet Planet Health. 2021 May;5(5):e277-e285. doi: 10.1016/S2542-5196(21)00030-9.
PubMed 33964237Kirstein OD, Ayora-Talavera G, Koyoc-Cardena E, Chan Espinoza D, Che-Mendoza A, Cohuo-Rodriguez A, Granja-Perez P, Puerta-Guardo H, Pavia-Ruz N, Dunbar MW, Manrique-Saide P, Vazquez-Prokopec GM. Natural arbovirus infection rate and detectability of indoor female Aedes aegypti from Merida, Yucatan, Mexico. PLoS Negl Trop Dis. 2021 Jan 4;15(1):e0008972. doi: 10.1371/journal.pntd.0008972. eCollection 2021 Jan.
PubMed 33395435Dzib-Florez S, Ponce-Garcia G, Medina-Barreiro A, Gonzalez-Olvera G, Contreras-Perera Y, Del Castillo-Centeno F, Ahmed AMM, Che-Mendoza A, McCall PJ, Vazquez-Prokopec G, Manrique-Saide P. Evaluating Over-the-Counter Household Insecticide Aerosols for Rapid Vector Control of Pyrethroid-Resistant Aedes aegypti. Am J Trop Med Hyg. 2020 Nov;103(5):2108-2112. doi: 10.4269/ajtmh.20-0515.
PubMed 32748782Dean NE, Crisp AM, Che-Mendoza A, Kirstein OD, Barrera-Fuentes GA, Earnest JT, Puerta-Guardo HN, Collins MH, Pavia-Ruz N, Ayora-Talavera G, Gonzalez-Olvera G, Medina-Barreiro A, Bibiano-Marin W, Jabbarzadeh S, Halloran ME, Longini IM Jr, Lenhart A, Waller LA, Correa-Morales F, Palacio-Vargas J, Gomez-Dantes H, Manrique-Saide P, Vazquez-Prokopec GM. Randomized Trial of Targeted Indoor Spraying to Prevent Aedes-Borne Diseases. N Engl J Med. 2025 Oct 9;393(14):1387-1398. doi: 10.1056/NEJMoa2501069.
PubMed 41061233
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases
- ClinicalTrials.gov ID
- NCT04343521
- Acronym / sponsor ID
- IRB00108666
- Conditions
- Aedes-borne Diseases, Dengue, Chikungunya, Zika
- Keywords
- Targeted Indoor Residual Spraying, Children, Dengue virus (DENV), Chikungunya virus (CHIKV), Zika virus (ZIKV), Ae. aegypti mosquito
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 4,461 participants (actual)
- Lead sponsor
- Emory UniversityUniversity, hospital or other
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- Study start
- 3 Nov 2020 (actual)
- Primary completion
- 28 Apr 2024 (actual)
- Study completion
- 28 Apr 2024 (actual)
- First posted
- 13 Apr 2020 (actual)
- Results
- Posted 18 Sep 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this trial is evaluate the efficacy of Targeted Indoor Residual Spraying (TIRS) in preventing symptomatic disease caused by Aedes-borne diseases (ABDs) in children 2 to 15 years of age in the city of Merida, Yucatan State, Mexico.
Detailed description
Contemporaneous urban vector control (truck-mounted ultra-low volume spraying, thermal fogging, larviciding) has failed to contain dengue epidemics and to prevent the global range expansion of Aedes-borne diseases (ABDs: dengue, chikungunya, zika). Part of the challenge in sustaining effective ABD control emerges from the remarkable paucity of evidence about the epidemiological impact of any vector control method. Furthermore, the classic deployment of interventions in response to clinical cases fails to account for the important contribution of out-of-home human mobility and asymptomatic infections.
The trial will be conducted in the city of Merida extending ongoing longitudinal cohort to follow a population of 4,600 children 2-15 years old randomly allocated to receive either TIRS treatment or not. If efficacious, TIRS will drive a paradigm shift in Aedes control by: considering Ae. aegypti behavior to rationally guide insecticide applications; the change to preventive control (pre- ABD transmission season rather than in response to symptomatic cases); the use of third generation insecticides to which Ae. Aegypti is susceptible.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Targeted Indoor Residual Spraying (TIRS) | Experimental | Other: Targeted Indoor Residual Spraying (TIRS)All households in Targeted Indoor Residual Spraying (TIRS) clusters will be offered the intervention, and children in households that consent to TIRS will be recruited into this study arm. |
| Routine Aedes-borne Virus (ABV) Prevention and Control | No intervention | –Households in the control clusters receive routine Aedes-borne virus (ABV) prevention and control, without Targeted Indoor Residual Spraying (TIRS). Children in the control households will be recruited into this study arm. |
Who may qualify
- Ages
- 2 to 15 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (6 listed)
- Household is located within the bounds of a study cluster (5x5 city-block clusters)
- City block has at least 60% premises that are residential
- 2 or more and up to 15 years of age at the time of initial enrollment
- Living in a house that consented to TIRS (for children in TIRS cluster)
Key exclusion criteria (11 listed)
- Households where study personnel identify a security risk (i.e., site where drugs are sold, residents are always drunk or hostile)
- Sites where no residents spend time during the day (i.e. work 7days a week outside the home)
- Inability for a resident to provide informed consent
- Non-residential places (e.g., businesses, schools, markets, etc.)
- Less than 2 years of age or more than 15 years of age at the time of enrollment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Targeted Indoor Residual Spraying (TIRS)Also: Actellic 300CSSpraying of insecticide Actellic 300CS will start in May or June extending for 1 to 2 months. Residents will be asked to temporarily leave the house during treatment and wait half an hour to one hour for the product to dry before re-entering the house. Insecticide application will follow strict protocol developed by the Centers for Disease Control and Prevention (CDC), Emory University, and the Universidad Autónoma de Yucatán. | Other | Targeted Indoor Residual Spraying (TIRS) |
Primary outcome
Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically
Time frame: 18 months of active surveillance during high transmission seasons (each 6 months in duration) during 3 years (July through December in 2021, 2022, and 2023)
The number of symptomatic children with laboratory confirmed, by reverse transcription-polymerase chain reaction (RT-PCR) or immunoglobulin M/ immunoglobulin G (IgM/IgG) enzyme-linked immunosorbent assay (ELISA), Aedes-borne Viruses infections. The number of any Aedes-borne virus infection during three seasons of high transmission is described, as well as the number of Dengue virus (DENV), Chikungunya virus (CHIKV), Zika virus (ZIKV) and coinfections.
7 secondary outcomes
Number Positive Tests of Laboratory Confirmed Aedes-borne Viruses Infections By Season
Time frame: Up to 36 months, during serosurvey seasons 2021-2022, 2022-2023, and 2023-2024
Ae. Aegypti Mosquito Infection Rate With Aedes-borne Viruses (DENV, CHIKV and ZIKV)
Time frame: Up to 6 months (mosquito pools were collected during the 6 months post TIRS spraying samplings in 2021)
Ae. Aegypti Indoor Entomological Index of Adult Mosquito Abundance
Time frame: Up to 36 months starting at the first TIRS application
Ae. Aegypti Indoor Entomological Index of Female Mosquito Abundance
Time frame: Up to 36 months starting at first TIRS application
Ae. Aegypti Indoor Entomological Index of Bloodfed Female Mosquito Abundance
Time frame: Up to 36 months starting at first TIRS application
Number of Households Where the Head of Household Would Recommend the Intervention
Time frame: Post-intervention (up to 41 months and 26 days after the start of the intervention)
Number of Households With a Resident That Had a Reaction to the Insecticide
Time frame: Post-intervention (up to 41 months and 26 days after the start of the intervention)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 33032661Manrique-Saide P, Dean NE, Halloran ME, Longini IM, Collins MH, Waller LA, Gomez-Dantes H, Lenhart A, Hladish TJ, Che-Mendoza A, Kirstein OD, Romer Y, Correa-Morales F, Palacio-Vargas J, Mendez-Vales R, Perez PG, Pavia-Ruz N, Ayora-Talavera G, Vazquez-Prokopec GM. The TIRS trial: protocol for a cluster randomized controlled trial assessing the efficacy of preventive targeted indoor residual spraying to reduce Aedes-borne viral illnesses in Merida, Mexico. Trials. 2020 Oct 8;21(1):839. doi: 10.1186/s13063-020-04780-7.
- Background: PubMed 34606519Che-Mendoza A, Gonzalez-Olvera G, Medina-Barreiro A, Arisqueta-Chable C, Bibiano-Marin W, Correa-Morales F, Kirstein OD, Manrique-Saide P, Vazquez-Prokopec GM. Efficacy of targeted indoor residual spraying with the pyrrole insecticide chlorfenapyr against pyrethroid-resistant Aedes aegypti. PLoS Negl Trop Dis. 2021 Oct 4;15(10):e0009822. doi: 10.1371/journal.pntd.0009822. eCollection 2021 Oct.
- Background: PubMed 33964237Dzul-Manzanilla F, Correa-Morales F, Che-Mendoza A, Palacio-Vargas J, Sanchez-Tejeda G, Gonzalez-Roldan JF, Lopez-Gatell H, Flores-Suarez AE, Gomez-Dantes H, Coelho GE, da Silva Bezerra HS, Pavia-Ruz N, Lenhart A, Manrique-Saide P, Vazquez-Prokopec GM. Identifying urban hotspots of dengue, chikungunya, and Zika transmission in Mexico to support risk stratification efforts: a spatial analysis. Lancet Planet Health. 2021 May;5(5):e277-e285. doi: 10.1016/S2542-5196(21)00030-9.
- Background: PubMed 33395435Kirstein OD, Ayora-Talavera G, Koyoc-Cardena E, Chan Espinoza D, Che-Mendoza A, Cohuo-Rodriguez A, Granja-Perez P, Puerta-Guardo H, Pavia-Ruz N, Dunbar MW, Manrique-Saide P, Vazquez-Prokopec GM. Natural arbovirus infection rate and detectability of indoor female Aedes aegypti from Merida, Yucatan, Mexico. PLoS Negl Trop Dis. 2021 Jan 4;15(1):e0008972. doi: 10.1371/journal.pntd.0008972. eCollection 2021 Jan.
- Background: PubMed 32748782Dzib-Florez S, Ponce-Garcia G, Medina-Barreiro A, Gonzalez-Olvera G, Contreras-Perera Y, Del Castillo-Centeno F, Ahmed AMM, Che-Mendoza A, McCall PJ, Vazquez-Prokopec G, Manrique-Saide P. Evaluating Over-the-Counter Household Insecticide Aerosols for Rapid Vector Control of Pyrethroid-Resistant Aedes aegypti. Am J Trop Med Hyg. 2020 Nov;103(5):2108-2112. doi: 10.4269/ajtmh.20-0515.
- Derived from this study: PubMed 41061233Dean NE, Crisp AM, Che-Mendoza A, Kirstein OD, Barrera-Fuentes GA, Earnest JT, Puerta-Guardo HN, Collins MH, Pavia-Ruz N, Ayora-Talavera G, Gonzalez-Olvera G, Medina-Barreiro A, Bibiano-Marin W, Jabbarzadeh S, Halloran ME, Longini IM Jr, Lenhart A, Waller LA, Correa-Morales F, Palacio-Vargas J, Gomez-Dantes H, Manrique-Saide P, Vazquez-Prokopec GM. Randomized Trial of Targeted Indoor Spraying to Prevent Aedes-Borne Diseases. N Engl J Med. 2025 Oct 9;393(14):1387-1398. doi: 10.1056/NEJMoa2501069.
- link to project websiteLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Deidentified individual participant data that underlie the results reported in publications of this study will be available for sharing with other researchers.
Related trials for Aedes-borne Diseases
Recruiting
Implementation and Evaluation of Vector Control Methods in Kinshasa: The Case of Aedes
Aedes-borne Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gonzalo Vazquez Prokopec, MD principal investigator
Emory University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Targeted Indoor Residual Spraying (TIRS) in people with Aedes-borne Diseases and Dengue, run by Emory University at 1 site in Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 18 Sep 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically (time frame: 18 months of active surveillance during high transmission seasons (each 6 months in duration) during 3 years (July through December in 2021, 2022, and 2023)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04343521, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2025; AzTrials last refreshed its copy on 7 Nov 2026.